Simile Raises $200M at $2B Valuation: Behavioral AI's Signal to Accredited Investors

TL;DR: Simile raised a $200 million Series B at a $2 billion valuation, just five months after a $100 million Series A. The Stanford spinout's behavioral AI platform grew revenue 5x since February 2026. For accredited investors tracking AI, the speed of this round is a signal — not just about one company, but about where institutional capital is concentrating in the enterprise software stack.

On August 1, 2026, Simile announced the close of a $200 million Series B co-led by Greenoaks Capital and Index Ventures, with participation from Bain Capital Ventures and CVS Health Ventures. The round values the company at $2 billion post-money. Simile launched publicly in February 2026 and had already raised a $100 million Series A earlier this year — meaning the company went from launch to $2 billion valuation in roughly six months.

That trajectory demands attention from anyone tracking early-stage enterprise AI.

What Simile Actually Does

Simile is a behavioral AI platform built for enterprise deployment. The company uses machine learning to predict and model human behavior at scale , how customers make decisions, how employees respond to organizational changes, how specific messages land across different population segments.

The company emerged from Stanford's Human-Computer Interaction research group. Its core thesis: behavioral prediction is more valuable than behavioral description. Most analytics tools tell you what happened. Simile tells you what will happen based on behavioral patterns across structured and unstructured data.

Early customers include Fortune 500 companies in healthcare, financial services, and consumer goods. CVS Health Ventures' participation in this round is not coincidental , behavioral modeling in pharmacy and clinical settings is a high-value application for a company that touches 200 million Americans annually.

The 5x Revenue Growth Signal

Simile's revenue grew 5x from its February 2026 launch to the Series B close in August 2026. The company has not disclosed exact revenue figures, but the 5x growth over roughly five months on a $200 million round at $2 billion post-money implies the investors priced in significant forward assumptions.

For context: a $2 billion valuation at a 20x revenue multiple implies $100 million in ARR. At 10x, the company would need $200 million in ARR. Neither figure is confirmed. What is confirmed is that Greenoaks, which built its reputation on concentrated bets in Coupang, Nubank, and Notion, led this round. Greenoaks does not price speculatively.

The Series A five months prior was led by separate investors. The fact that this round attracted a new lead at a 2x step-up to the Series A valuation means the business showed measurable growth between rounds, not just narrative improvement.

Why This Round Matters for Accredited Investors

Most accredited investors cannot invest directly in a private company at the Series B stage unless they have an existing relationship with the lead investors or a placement agent connection. Simile is not running a Regulation Crowdfunding campaign.

But the round matters for three reasons.

First, it confirms that behavioral AI is crystallizing as a standalone enterprise category. When Greenoaks, Index, and Bain all pile into the same company at speed, they are placing a category bet , not just a company bet. The winner of this category will be worth multiples of $2 billion in five to eight years.

Second, it signals where enterprise software buying budgets are moving. CVS Health participating with its corporate VC validates that large healthcare and consumer companies are actively budgeting for behavioral AI tools. That spend typically ripples down to SMB and mid-market products within two to three years.

Third, it changes the public market entry point calculus. If Simile files for an IPO in 2027 or 2028, accredited investors who track the company now have months of history to evaluate before a public offering. Pre-IPO secondary market transactions on platforms like Forge or EquityZen often become available for late-stage companies like this within six to twelve months of a major fundraise.

The Competitive Landscape

Simile is not alone in behavioral AI. Mixpanel and Amplitude are publicly traded companies with behavioral analytics products. Qualtrics, acquired by SAP and then taken private by Silver Lake in 2023, covers experience data. Palantir covers behavioral modeling at the government and defense level.

What Simile claims to do differently is predictive depth , moving beyond event tracking and survey data to genuine behavioral prediction using foundation model architectures trained on enterprise data. Whether that moat holds as OpenAI, Anthropic, and Google build increasingly capable models is the central risk in the thesis.

The hedged answer: the behavioral AI layer for enterprises is real. The specific moat of any single company in it is not yet proven at scale.

What to Watch in AI Investing in H2 2026

The Simile round is one data point in a broader pattern. Three things are happening simultaneously in enterprise AI investing:

• Speed compression: Companies are going from seed to Series B in 12-18 months instead of 36-48 months. This compresses the time window for accredited investors to identify winners before institutional capital locks them out.
• Category bifurcation: Infrastructure AI (compute, training, inference) is dominated by hyperscalers and a few well-capitalized specialists. Application layer AI is still fragmented and accessible to early-stage investing.
• Revenue quality matters more than revenue growth: The best investors in this cycle are asking whether AI revenue is recurring, contracted, and expanding , not just growing. Net dollar retention above 120% is the benchmark for top-quartile SaaS.

Simile's 5x growth in five months is a headline. Whether the underlying revenue cohorts are contracting, stagnant, or expanding will determine the company's long-term value.

The Risk That Does Not Get Discussed

Stanford-founded AI companies come with a specific risk profile. Research spinouts are exceptional at building technically sophisticated products. They are often slow to build the commercial infrastructure , sales teams, customer success, pricing discipline , that turns research into enterprise revenue at scale.

Greenoaks and Bain are experienced enough to have priced this risk in, and presumably to be actively building the commercial function alongside the technical team. But for accredited investors evaluating whether to seek pre-IPO exposure to Simile or comparable companies, the question to ask is not just "how good is the model" but "how good is the go-to-market team."

Frequently Asked Questions

Q: Can accredited investors invest in Simile directly?
A: Not through a public offering. Secondary market platforms like Forge and EquityZen occasionally offer shares in late-stage private companies after major fundraising events, typically 6-12 months after the round. Monitor these platforms for Simile listings.

Q: What is behavioral AI vs. generative AI?
A: Generative AI creates new content (text, images, code). Behavioral AI analyzes patterns in human actions and decisions to predict future behavior. They use some overlapping architectures but serve different enterprise functions.

Q: What does Greenoaks leading the round signal?
A: Greenoaks is a concentrated, high-conviction growth fund that led early rounds in Coupang, Nubank, and Notion. Their involvement signals conviction that Simile is addressing a large addressable market with defensible technology, not just another AI wrapper.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.